Astria Therapeutics, Inc. (ATXS) Tops Q3 EPS by 16c; Reports Cash and Cash Equivalents of $131.8M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
November 10, 2021 8:00 AM EST-- STAR-0215, in Development to Treat HAE, on Track for Initial Phase 1 Clinical Results Expected by Year End 2022 --
-- New Preclinical Data on STAR-0215 Demonstrating High Potency and Extended Plasma Half-Life --
-- Findings on Burdens of Disease and Treatment in HAE Support Substantial Need to Decrease Patient Burden --
BOSTON--(BUSINESS... More
